Zacks: Clementia Pharmaceuticals (CMTA) Receives Consensus Rating of “Strong Buy” from Analysts

Clementia Pharmaceuticals (NASDAQ:CMTA) has been assigned an average broker rating score of 1.13 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and three have issued a strong buy rating on the company.

Brokerages have set a 12-month consensus target price of $27.00 for the company and are predicting that the company will post ($0.33) EPS for the current quarter, according to Zacks. Zacks has also given Clementia Pharmaceuticals an industry rank of 185 out of 265 based on the ratings given to its competitors.

How to Become a New Pot Stock Millionaire

Separately, Zacks Investment Research cut Clementia Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th.

Institutional investors and hedge funds have recently modified their holdings of the stock. Orbimed Advisors LLC purchased a new position in Clementia Pharmaceuticals in the 3rd quarter worth about $176,082,000. JPMorgan Chase & Co. purchased a new position in Clementia Pharmaceuticals in the 3rd quarter worth about $10,937,000. Sectoral Asset Management Inc purchased a new position in Clementia Pharmaceuticals during the 3rd quarter valued at about $512,000. Citadel Advisors LLC purchased a new position in Clementia Pharmaceuticals during the 3rd quarter valued at about $2,061,000. Finally, Susquehanna International Group LLP purchased a new position in Clementia Pharmaceuticals during the 3rd quarter valued at about $729,000. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Clementia Pharmaceuticals (CMTA) traded up $0.27 on Friday, reaching $17.34. The company had a trading volume of 1,788 shares, compared to its average volume of 78,674. Clementia Pharmaceuticals has a 1 year low of $11.72 and a 1 year high of $20.15.

ILLEGAL ACTIVITY WARNING: This report was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3302438/zacks-clementia-pharmaceuticals-cmta-receives-consensus-rating-of-strong-buy-from-analysts.html.

Clementia Pharmaceuticals Company Profile

Clementia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. Its lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models.

Get a free copy of the Zacks research report on Clementia Pharmaceuticals (CMTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clementia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clementia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Purple Innovation  Receiving Positive Media Coverage, Analysis Shows
Purple Innovation Receiving Positive Media Coverage, Analysis Shows
Traders Buy Shares of SPDR Gold Shares  on Weakness
Traders Buy Shares of SPDR Gold Shares on Weakness
Investors Buy Visa  on Weakness
Investors Buy Visa on Weakness
Investors Buy Shares of iShares 7-10 Year Treasury Bond ETF  on Weakness
Investors Buy Shares of iShares 7-10 Year Treasury Bond ETF on Weakness
CoinPoker Trading 6.1% Higher  This Week
CoinPoker Trading 6.1% Higher This Week
UNCoin 24 Hour Trading Volume Hits $0.00
UNCoin 24 Hour Trading Volume Hits $0.00


© 2006-2018 Ticker Report. Google+.